Trial Profile
Phase 1b exploratory study of [18F]AH111585-PET as a marker of angiogenic response to combination therapy with the pan-VEGF inhibitor, pazopanib, and weekly paclitaxel in platinum resistant ovarian cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pazopanib (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms PAZ-PET; PAZPET-1
- Sponsors GSK
- 04 Jun 2019 Results (n=14) assessing clinical response of combination therapy pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 09 Mar 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.